Category Archives: Meetings

[Extended] Call for applicants Adolescent, Pediatric and Adult Community Advisory Board (CAB) Member THRIVE AHD Project

Edit The THRIVE consortium (Transforming Advanced HIV Disease CaRe in LMICs through Comprehensive and Equitable Access) – comprised of CHAI, Afrocab, Penta and operational research partners Zvitambo and Mildmay Uganda – was formed to dramatically reduce mortality among adults and CLHIV by enabling global access to critical prevention, screening, and treatment commodities, and centring local […]

Comments closed Edit

Call for applications Adolescent, Pediatric and Adult Community Advisory Board (CAB) Members THRIVE AHD Project

The THRIVE consortium (Transforming Advanced HIV Disease CaRe in LMICs through Comprehensive and Equitable Access) – comprised of CHAI, Afrocab, Penta and operational research partners Zvitambo and Mildmay Uganda – was formed to dramatically reduce mortality among adults and CLHIV by enabling global access to critical prevention, screening, and treatment commodities, and centring local leadership […]

Comments closed Edit

Consultancy: Salary, Benefits and Remuneration Benchmarking

Afrocab Treatment Access Partnership (Afrocab) is seeking a consultant to conduct a benchmarking exercise to provide a recommendation for the salary, benefits and remuneration structure aligned to current market pay for a multi-country regional network organization. For requirements, how to apply and detailed consultancy descriptions, click on the link below:

Comments closed Edit

Afrocab is recruiting!

Afrocab has openings for a Technical Director, Finance and Administration Manager and Administrative Associate. For requirements, how to apply and detailed job descriptions, click on the links below:

Comments closed Edit

Dolutegravir-Based ART — Effective for HIV-2 Infection

In a small single-arm, open-label trial in Portugal, dolutegravir + two NRTIs proved effective and safe for managing HIV-2 infection. Data are sparse regarding treatment of HIV-2 infection with contemporary ART regimens; moreover, HIV-2 exhibits intrinsic resistance to NNRTIs. Further complicating the management of HIV-2 infection is the fact that plasma HIV-2 RNA levels, when […]

Comments closed Edit

Open Letter: Community Statement on Accelerating Access to Lenacapavir by Gilead

We are sharing a statement from a community and civil society leaders, advocates and activists meeting on long-acting drugs for the prevention and treatment of HIV which took place in Nairobi in April 2023.In this statement, the community demands rapid action from Gilead to make Lenacapavir accessible in low and middle-income countries without further delay! […]

Comments closed Edit

CALL FOR APPLICATIONS SMART4TB CAB MEMBERSHIP 2023-2027

Greetings from Afrocab, SMART4TB is a US$200 million investment from USAID to tackle tuberculosis (TB) through research and its translation to policy and practice. The SMART4TB project is led by Johns Hopkins University and an international consortium of research partners and civil society organizations. SMART4TB will run through 2027 and will support research across five […]

Comments closed Edit

AFROCAB COMMUNITY FORUM: Supporting Affordable Access to Long-Acting Technologies; the Future of HIV Prevention and Treatment

In April 2023, the CAB hosted a meeting on long-acting technologies and introduction pathways. Presentations, discussions, and panel sessions featured CAB members, Ministry of Health officials, and supplier and industry representatives across two days. The sessions covered key focal areas across the product introduction pathway to inform a third and final day of work-planning and advocacy […]

Comments closed Edit

An Open Letter to WHO on access to DRV/r 400/50 mg in LMICs

On behalf of community stakeholders, Afrocab Treatment Access Partnership shared an open letter with the WHO as a follow-up to a community and advocates sign-on letter released on 3rd December 2022.  The statement called on WHO and others to accelerate access to DRV/r in the second line of HIV treatment. The community notes that since […]

Comments closed Edit

Darunavir/ritonavir (DRV/r) Advocacy!

In December 2021, HIV advocates from around the world demanded access to an optimal second-line medicine called darunavir/ritonavir (DRV/r), which has been used in high-income countries for over 15 years but only just recently became available outside of wealthy nations. Few countries, primarily Nigeria and Zambia, have begun to use DRV/r, but widespread access and […]

Comments closed Edit